Table 1 Characteristics of included studies
Study | Country | Period | Study design | Inclusion criteria | ECMO group of children with underlying malignancies |
|---|---|---|---|---|---|
Lindén et al. 1999 [19] | Sweden | NR | Retro, single center | Underlying malignancy and PCP pneumonia | 4 |
Gupta et al. 2008 [20] | ELSO registry | 1985–2004 | Retro, multicenter ELSO registry | Immunocompromised condition and respiratory failure as indication for ECMO Age 30 days–19 yrs | 60 |
Gow et al. 2009 [21] | ELSO registry | 1992–2007 | Retro, multicenter ELSO registry | Underlying malignancy Age < 21 yrs | 107 |
Meister et al. 2009 [22] | Austria | NR | Retro, single center | Leukemia | 4 |
Di Nardo et al. 2014 [23] | ELSO registry | 1991–2012 | Retro, multicenter ELSO registry | HSCT patients Age < 18 yrs | 15 |
Smith et al. 2016 [24] | Australia | 1993–2014 | Retro, single center | Pediatric cancer patients with neutropenic sepsis | 9 |
Bailly et al. 2017 [25] | ELSO registry | 2001–2013 | Retro, multicenter ELSO registry | ECMO for respiratory failure due to a primary pulmonary diagnosis Age 7 days–18 yrs | 161 |
Cortina et al. 2018 [26] | Austria | 2004–2007 | Retro, single center | Leukemia | 9 |
Maue et al. 2019 [27] | USA | 2011–2016 | Retro, single center | Pediatric oncology and/or HSCT patients | 5 |
Steppan et al. 2020 [28] | USA | 2011–2018 | Retro, multicenter PEDECOR registry | Pediatric oncology and/or HSCT patients | 16 |
Ranta et al. 2020 [29] | Sweden | 2008–2016 | Retro, multicenter | Hematological malignancies | 12 |
Coleman et al. 2020 [30] | USA | 2004–2013 | Retro, multicenter PHIS registry | Underlying malignancy, genetic disorders or high-risk congenital heart disease | 200 |
Friedman et al. 2020 [31] | USA | 2011–2016 | Retro, multicenter | Patients requiring VV-ECMO Age 14 days-18 yrs | 23 |